Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2876322 | 0.93 | CYP4F2 (0.41) | CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL11033875 | 0.82 | CYP4F2 (0.41) | CYP4F2CYP4A11 | |
| SCHEMBL2876067 | 0.80 | CYP4F2 (0.39) | CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL2824808 | 0.75 | CYP4F2 (0.41) | CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL20730162 | 0.75 | CYP4F2 (0.65) | CYP4F2CYP4A11 | |
| SCHEMBL6268373 | 0.75 | CYP4F2 (0.70) | CYP4F2CYP4A11 | |
| SCHEMBL19192596 | 0.73 | CYP4F2 (0.41) | CYP4F2CYP4A11 | |
| SCHEMBL9959210 | 0.73 | CYP2C19 (0.38) | — | |
| SCHEMBL17896044 | 0.70 | SMN1; SMN2 (0.39) | SMN1; SMN2 | |
| SCHEMBL17892801 | 0.70 | SMN1; SMN2 (0.39) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763980-B1 | BICARBOCYCLIC AND TRICARBOCYCLIC ETHYNYL DERIVATIVES AND USES OF SAME | H LUNDBECK AS (DK) | 2018-04-25 | — | — | EP | disclosed |
| EP-3263566-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AS ALLOSTERIC MODULATORS OF THE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5 OR MGLUR5) FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) DISORDERS | H. Lundbeck A/S (DK) | 2018-01-03 | — | — | EP | disclosed |
| US-20170217950-A1 | Bicyclo[3.2.1]Octyl Amide Derivatives and Uses of Same | H. LUNDBECK A/S (DK) | 2017-08-03 | — | — | US | disclosed |
| EP-2654422-B1 | Bicyclo[3.2.1]octyl amide derivatives as allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5 or mGluR5) for the treatment of central nervous system (CNS) disorders | H LUNDBECK AS (DK) | 2017-08-02 | — | — | EP | disclosed |
| US-9656975-B2 | Bicyclo[3.2.1]octyl amide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2017-05-23 | — | — | US | disclosed |
| US-20160326154-A1 | BICARBOCYCLIC AND TRICARBOCYCLIC ETHYNYL DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2016-11-10 | — | — | US | disclosed |
| US-9212165-B2 | Bicarbocyclic and tricarbocyclic ethynyl derivatives and uses of same | H. LUNDBECK A/S (DK) | 2015-12-15 | — | — | US | disclosed |
| US-20150057289-A1 | BICYCLO[3.2.1.]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2015-02-26 | — | — | US | disclosed |
| US-8921370-B2 | Bicyclo[3.2.1]octyl amide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-12-30 | — | — | US | disclosed |
| US-20140350030-A1 | BICARBOCYCLIC AND TRICARBOCYCLIC ETHYNYL DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2014-11-27 | — | — | US | disclosed |
| EP-2654422-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. Lundbeck A/S (DK) | 2013-10-30 | — | — | EP | disclosed |
| US-20120190686-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| WO-2012088365-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217950-A1 | Bicyclo[3.2.1]Octyl Amide Derivatives and Uses of Same | SLC10A1, CLIC1, ABCB11 | CYP4F2 887/4885CYP4A11 330/4885SMN1; SMN2 3159/4885 |
| US-20150057289-A1 | BICYCLO[3.2.1.]OCTYL AMIDE DERIVATIVES AND USES OF SAME | SLC10A1, CLIC1, ABCB11 | CYP4F2 1158/4885CYP4A11 465/4885SMN1; SMN2 2549/4885 |
| US-20120190686-A1 | BICYCLO[3.2.1]OCTYL AMIDE DERIVATIVES AND USES OF SAME | SLC10A1, CLIC1, ABCB11 | CYP4F2 887/4885CYP4A11 330/4885SMN1; SMN2 3159/4885 |
| US-20140350030-A1 | BICARBOCYCLIC AND TRICARBOCYCLIC ETHYNYL DERIVATIVES AND USES OF SAME | CBR1, CYCS, CYP3A43 | CYP4F2 91/4885CYP4A11 50/4885SMN1; SMN2 2389/4885 |
| US-20160326154-A1 | BICARBOCYCLIC AND TRICARBOCYCLIC ETHYNYL DERIVATIVES AND USES OF SAME | CBR1, CYCS, CYP3A43 | CYP4F2 91/4885CYP4A11 50/4885SMN1; SMN2 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.